Expansion of HAART coverage is associated with sustained decreases in HIV/AIDS morbidity, mortality and HIV transmission: the "HIV Treatment as Prevention" experience in a Canadian setting.
<h4>Background</h4>There has been renewed call for the global expansion of highly active antiretroviral therapy (HAART) under the framework of HIV treatment as prevention (TasP). However, population-level sustainability of this strategy has not been characterized.<h4>Methods</h4...
| Published in: | PLoS ONE |
|---|---|
| Main Authors: | Julio S G Montaner, Viviane D Lima, P Richard Harrigan, Lillian Lourenço, Benita Yip, Bohdan Nosyk, Evan Wood, Thomas Kerr, Kate Shannon, David Moore, Robert S Hogg, Rolando Barrios, Mark Gilbert, Mel Krajden, Reka Gustafson, Patricia Daly, Perry Kendall |
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2014-01-01
|
| Online Access: | https://doi.org/10.1371/journal.pone.0087872 |
Similar Items
Cost-Effectiveness of Antiretroviral Therapy for Multidrug-Resistant HIV: Past, Present, and Future
by: Marianne Harris, et al.
Published: (2012-01-01)
by: Marianne Harris, et al.
Published: (2012-01-01)
Aboriginal status is a prognostic factor for mortality among antiretroviral naïve HIV-positive individuals first initiating HAART
by: Daniel Mark, et al.
Published: (2006-05-01)
by: Daniel Mark, et al.
Published: (2006-05-01)
Clinical Features, Treatment, and Outcome of HIV-Associated Immune Thrombocytopenia in the HAART Era
by: Kimberley L. S. Ambler, et al.
Published: (2012-01-01)
by: Kimberley L. S. Ambler, et al.
Published: (2012-01-01)
The Impact of HIV on Maternal Morbidity in the Pre-HAART Era in Uganda
by: Harriet Nuwagaba-Biribonwoha, et al.
Published: (2012-01-01)
by: Harriet Nuwagaba-Biribonwoha, et al.
Published: (2012-01-01)
High levels of heterogeneity in the HIV cascade of care across different population subgroups in British Columbia, Canada.
by: Lillian Lourenço, et al.
Published: (2014-01-01)
by: Lillian Lourenço, et al.
Published: (2014-01-01)
A Comparative Study of Salivary Composition of HIV Seropositive Patients on HAART and Not on HAART
by: Navdeep Johar, et al.
Published: (2011-01-01)
by: Navdeep Johar, et al.
Published: (2011-01-01)
Lipodystrophy syndrome in HIV-infected children on HAART
by: Steve Innes, et al.
Published: (2009-12-01)
by: Steve Innes, et al.
Published: (2009-12-01)
Relationship between Body Mass Index and Mortality in HIV-Infected HAART Users in the Women's Interagency HIV Study.
by: Anjali Sharma, et al.
Published: (2015-01-01)
by: Anjali Sharma, et al.
Published: (2015-01-01)
Causes of hypercalcemia in people living with HIV in the HAART era
by: Arkom Nongnuch, et al.
Published: (2020-10-01)
by: Arkom Nongnuch, et al.
Published: (2020-10-01)
Neurologic complications of HIV in the HAART era: where are we?
by: Monica M. Gomes da Silva
by: Monica M. Gomes da Silva
Kaposi Sarcoma of the Eye in an HIV Patient Well-responded to HAART
by: Erni J Nelwan, et al.
Published: (2016-05-01)
by: Erni J Nelwan, et al.
Published: (2016-05-01)
Kaposi Sarcoma of the Eye in an HIV Patient Well-responded to HAART
by: Erni J Nelwan, et al.
Published: (2016-05-01)
by: Erni J Nelwan, et al.
Published: (2016-05-01)
Genetic Markers Associated to Dyslipidemia in HIV-Infected Individuals on HAART
by: Rosmeri K. Lazzaretti, et al.
Published: (2013-01-01)
by: Rosmeri K. Lazzaretti, et al.
Published: (2013-01-01)
Intensive Care Usage by HIV-Positive Patients in the HAART Era
by: L. Turtle, et al.
Published: (2011-01-01)
by: L. Turtle, et al.
Published: (2011-01-01)
HIV-1 infection in dendritic cells in HAART suppressed patients
by: Cornier Alberto S, et al.
Published: (2006-12-01)
by: Cornier Alberto S, et al.
Published: (2006-12-01)
HIV Positivity Disclosure Among Children Living with HIV/AIDS and Currently on HAART in Dessie, Northeast Ethiopia
by: Chanie MG, et al.
Published: (2022-10-01)
by: Chanie MG, et al.
Published: (2022-10-01)
HIV-1 tropism in low-level viral load HIV-1 infections during HAART in Guangdong, China
by: Chuyu Zhang, et al.
Published: (2023-04-01)
by: Chuyu Zhang, et al.
Published: (2023-04-01)
Adherence to Highly Active Antiretroviral Therapy (HAART) in HIV/AIDS Patient
by: Erni J Nelwan
Published: (2014-10-01)
by: Erni J Nelwan
Published: (2014-10-01)
Adherence to Highly Active Antiretroviral Therapy (HAART) in HIV/AIDS Patient
by: Erni J Nelwan
Published: (2014-10-01)
by: Erni J Nelwan
Published: (2014-10-01)
Influence of Age and Neurotoxic HAART Use on Frequency of HIV Sensory Neuropathy
by: Olajumoke Oshinaike, et al.
Published: (2012-01-01)
by: Olajumoke Oshinaike, et al.
Published: (2012-01-01)
Immunotoxin complementation of HAART to deplete persisting HIV-infected cell reservoirs.
by: Edward A Berger, et al.
Published: (2010-06-01)
by: Edward A Berger, et al.
Published: (2010-06-01)
HAART and Liver: A Discussion of Hepatic Disease in those Living with HIV
by: Curtis Cooper, et al.
Published: (2008-01-01)
by: Curtis Cooper, et al.
Published: (2008-01-01)
Respiratory symptoms and airway obstruction in HIV-infected subjects in the HAART era.
by: M Patricia George, et al.
Published: (2009-07-01)
by: M Patricia George, et al.
Published: (2009-07-01)
2228 The association of gastrointestinal symptoms and hypertension in persons living with HIV on HAART
by: Kierra R. Butler, et al.
Published: (2018-06-01)
by: Kierra R. Butler, et al.
Published: (2018-06-01)
Physician's manual reporting underestimates mortality: evidence from a population-based HIV/AIDS treatment program
by: Yip Benita, et al.
Published: (2010-10-01)
by: Yip Benita, et al.
Published: (2010-10-01)
Are Interferon-Free Direct-Acting Antivirals for the Treatment of HCV Enough to Control the Epidemic among People Who Inject Drugs?
by: Viviane D Lima, et al.
Published: (2015-01-01)
by: Viviane D Lima, et al.
Published: (2015-01-01)
Opportunistic Cryptococcal Antigenemia in the HAART Era at HIV Epidemic Settings of Northwest Ethiopia
by: Markos Negash, et al.
Published: (2020-01-01)
by: Markos Negash, et al.
Published: (2020-01-01)
Diabetes mellitus and associated risk factors among HIV infected patients on HAART
by: Lucy Kanyara, et al.
Published: (2024-03-01)
by: Lucy Kanyara, et al.
Published: (2024-03-01)
Ocularhaemodynamics parameters of asymptomatic HAART experienced HIV-infected under-five children
by: Ajulo MO, et al.
Published: (2024-07-01)
by: Ajulo MO, et al.
Published: (2024-07-01)
HAART treatment with free provided medications for people living with HIV in Huzhou, China
by: Xiaofeng Li, et al.
Published: (2024-11-01)
by: Xiaofeng Li, et al.
Published: (2024-11-01)
Assessing the effect of HAART on change in quality of life among HIV-infected women
by: Hu Zheng, et al.
Published: (2006-03-01)
by: Hu Zheng, et al.
Published: (2006-03-01)
Fundus manifestations and HIV viral loads of AIDS patients before and after HAART
by: Yu Di, et al.
Published: (2019-09-01)
by: Yu Di, et al.
Published: (2019-09-01)
The influence of HCV coinfection on clinical, immunological and virological responses to HAART in HIV-patients
by: Ricardo A. Carmo, et al.
by: Ricardo A. Carmo, et al.
Analysis of General Humoral Immunity HIV Dynamics Model with HAART and Distributed Delays
by: A. M. Elaiw, et al.
Published: (2019-02-01)
by: A. M. Elaiw, et al.
Published: (2019-02-01)
Pre-HAART CD4+ T-lymphocytes as biomarkers of post-HAART immune recovery in HIV-infected children with or without TB co-infection
by: Vivek Gopalakrishnan, et al.
Published: (2020-10-01)
by: Vivek Gopalakrishnan, et al.
Published: (2020-10-01)
Nutritional status of HIV-positive individuals on free HAART treatment in a developing nation
by: Samuel Nnamdi Obi, et al.
Published: (2010-08-01)
by: Samuel Nnamdi Obi, et al.
Published: (2010-08-01)
Evaluation of Fundoscopic Findings in HIV Positive Patients in Relation to HAART and CD4 Count
by: Ajit Kamalakar Joshi, et al.
Published: (2018-10-01)
by: Ajit Kamalakar Joshi, et al.
Published: (2018-10-01)
Impact of HAART Therapy and HIV Infection over Fetal Growth—An Anthropometric Point of View
by: Daniela Roxana Matasariu, et al.
Published: (2022-05-01)
by: Daniela Roxana Matasariu, et al.
Published: (2022-05-01)
Dyslipidemia and associated risk factors among HIV/AIDS patients on HAART in Asmara, Eritrea.
by: Oliver Okoth Achila, et al.
Published: (2022-01-01)
by: Oliver Okoth Achila, et al.
Published: (2022-01-01)
Fatores associados à adesão ao haart em pacientes com HIV/aids
by: Janaina Aparecida S Casotti, et al.
Published: (2011-10-01)
by: Janaina Aparecida S Casotti, et al.
Published: (2011-10-01)
Similar Items
-
Cost-Effectiveness of Antiretroviral Therapy for Multidrug-Resistant HIV: Past, Present, and Future
by: Marianne Harris, et al.
Published: (2012-01-01) -
Aboriginal status is a prognostic factor for mortality among antiretroviral naïve HIV-positive individuals first initiating HAART
by: Daniel Mark, et al.
Published: (2006-05-01) -
Clinical Features, Treatment, and Outcome of HIV-Associated Immune Thrombocytopenia in the HAART Era
by: Kimberley L. S. Ambler, et al.
Published: (2012-01-01) -
The Impact of HIV on Maternal Morbidity in the Pre-HAART Era in Uganda
by: Harriet Nuwagaba-Biribonwoha, et al.
Published: (2012-01-01) -
High levels of heterogeneity in the HIV cascade of care across different population subgroups in British Columbia, Canada.
by: Lillian Lourenço, et al.
Published: (2014-01-01)
